Inventor · disambiguated record
Chia-Yang Lin
Also filed as: LIN CHIA-YANG
26 granted patents·38 pending applications·37 citations·filing 2007–2025
94Inventor score
Top patents by PatentIndex Score
64 records- 0196US12180272B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2022·Granted Dec 31, 2024·2 cites·11 claims
- 0296US11708407B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2022·Granted Jul 25, 2023·2 cites·26 claims
- 0395US11725034B2IL2 agonists and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Aug 15, 2023·4 cites·30 claims
- 0494US12065508B2Multispecific antigen-binding molecules for cell targeting and uses thereofREGENERON PHARMA·Filed 2022·Granted Aug 20, 2024·3 cites·25 claims
- 0594US11952430B2Multispecific antigen-binding molecules for cell targeting and uses thereofREGENERON PHARMA·Filed 2022·Granted Apr 9, 2024·3 cites·24 claims
- 0693US12077603B2Multispecific antigen-binding molecules for cell targeting and uses thereofREGENERON PHARMA·Filed 2020·Granted Sep 3, 2024·3 cites·28 claims
- 0792US12391753B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2024·Granted Aug 19, 2025·0 cites·22 claims
- 0891US2025333492A1Antigen binding molecule formatsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0990US12331109B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2024·Granted Jun 17, 2025·0 cites·23 claims
- 1088US2024400632A1Novel il2 agonists and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1187US12091440B2IL2 and peptide-MHC complex fusion proteins and methods of use thereofREGENERON PHARMA·Filed 2020·Granted Sep 17, 2024·1 cites·33 claims
- 1287US11965020B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2023·Granted Apr 23, 2024·0 cites·24 claims
- 1387US2025289883A1Novel antigen binding molecule formatsREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1487US2025034224A1Novel il2 agonists and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1585US12215131B2IgG Fc-IL2-Rα-IL2 fusions and methods of use thereofREGENERON PHARMA·Filed 2023·Granted Feb 4, 2025·0 cites·25 claims
- 1683US11912767B2EGFR × CD28 multispecific antibodiesREGENERON PHARMA·Filed 2020·Granted Feb 27, 2024·1 cites·16 claims
- 1783US2024368312A1Multispecific antigen-binding molecules for cell targeting and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1883US2023312665A1Novel il2 agonists and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1981US12319724B2IL2 agonists and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Jun 3, 2025·0 cites·13 claims
- 2081US10869924B2PD-L1 antagonist combination treatmentsMERCK PATENT GMBH·Filed 2016·Granted Dec 22, 2020·6 cites·24 claims
- 2181US9248189B2Anti-glucagon receptor antibodies and pharmaceutical compositions thereofRINAT NEUROSCIENCE CORP·Filed 2014·Granted Feb 2, 2016·5 cites·14 claims
- 2277US8298535B2Anti-IL-7 receptor antibodiesLIN CHIA-YANG·Filed 2011·Granted Oct 30, 2012·5 cites·10 claims
- 2376US12240908B2N-terminal scFv multispecific binding moleculesREGENERON PHARMA·Filed 2022·Granted Mar 4, 2025·0 cites·10 claims
- 2475US12415856B2EGFR x CD28 multispecific antibodiesREGENERON PHARMA·Filed 2023·Granted Sep 16, 2025·0 cites·10 claims
- 2570US12274747B2Compositions and methods for treating cytokine release syndromeREGENERON PHARMA·Filed 2022·Granted Apr 15, 2025·0 cites·33 claims
- 2670US8637273B2Nucleic acid encoding IL-7 receptor alpha antibodyRINAT NEUROSCIENCE CORP·Filed 2012·Granted Jan 28, 2014·1 cites·14 claims
- 2770US2024067691A1Interferon receptor agonists and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2870US2024101633A1Interferon receptor agonists and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2969US12240907B2N-terminal scFv multispecific binding moleculesREGENERON PHARMA·Filed 2020·Granted Mar 4, 2025·0 cites·18 claims
- 3068US2025011449A1Circularized antibody moleculesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3168US2025171545A1N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULESREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3268US2024252601A1Ace2 fusion proteins and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3366US2024287162A1Multivalent anti-spike protein binding molecules and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3466US2024309072A1Multivalent anti-spike protein binding molecules and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3566US2024307512A1ACE2-IgM-Fc FUSION PROTEINS AND USES THEREOFREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3665US2024376229A1Interferon receptor antagonists and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3765US2024287186A1T cell activators and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3865US2023382969A1Interleukin-2 proproteins and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3964US12459991B2Compositions and methods for using bispecific antibodies to bind complement and a target antigenREGENERON PHARMA·Filed 2020·Granted Nov 4, 2025·0 cites·7 claims
- 4064US2024400687A1Cd20-pd1 binding molecules and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4164US2025340668A1Multispecific binding molecule proproteins and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4263US10023649B2Method of treating cancer with a combination of an anti-CCR4 antibody and a 4-1BB agonistPFIZER·Filed 2015·Granted Jul 17, 2018·1 cites·24 claims
- 4363US2024247069A1Fgfr3 binding molecules and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4463US2023391844A1Interleukin-2 proproteins and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4561US9346885B2Method of treating type 1 diabetes with antagonist IL-7 receptor antibodiesRINAT NEUROSCIENCE CORP·Filed 2013·Granted May 24, 2016·0 cites·10 claims
- 4661US2023357446A1Compositions and methods for universal tumor cell killingREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4761US2025302949A1Compositions and methods for treating cytokine release syndromeREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 4860US2025109207A1Chimeric heavy chain constant domains with reduced binding to fc gamma receptors and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4960US2018327503A1Antagonist anti-il-7 receptor antibodies and methodsRINAT NEUROSCIENCE CORP·Filed 2018·Application pending·0 cites
- 5057US10059772B2Antagonist anti-IL-7 receptor antibodies and methodsRINAT NEUROSCIENCE CORP·Filed 2016·Granted Aug 28, 2018·0 cites·1 claims
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Chia-Yang Lin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →